162 related articles for article (PubMed ID: 29685620)
1. Medical Management of a Prolactinoma in a 15-Year-Old Girl.
Bowling MS; Zamudio A; Jaffery F
J Pediatr; 2018 Sep; 200():287-287.e1. PubMed ID: 29685620
[No Abstract] [Full Text] [Related]
2. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
3. Visual vignette. Prolactinoma.
Mayrin JV; Donahue JE; Laufgraben MJ
Endocr Pract; 2008 Mar; 14(2):256. PubMed ID: 18308671
[No Abstract] [Full Text] [Related]
4. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
5. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
[TBL] [Abstract][Full Text] [Related]
6. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
[TBL] [Abstract][Full Text] [Related]
7. Mean platelet volume in patients with prolactinoma.
Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
10. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
12. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
13. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
[TBL] [Abstract][Full Text] [Related]
14. Sjögren's Syndrome Accompanied by Prolactinoma: a case report and literature review.
Oh YJ; Lee WS; Yoo WH; Hahm JR; Kim HO; Suh YS; Lee SI; Cheon YH
Int J Rheum Dis; 2017 Nov; 20(11):1823-1826. PubMed ID: 26355497
[No Abstract] [Full Text] [Related]
15. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
[TBL] [Abstract][Full Text] [Related]
16. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
[TBL] [Abstract][Full Text] [Related]
17. Clinical practice. Prolactinomas.
Klibanski A
N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
[No Abstract] [Full Text] [Related]
18. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
19. Prolactinoma presenting as painful postganglionic Horner syndrome.
Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
[No Abstract] [Full Text] [Related]
20. Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
Montalvo I; Llorens M; Caparrós L; Pamias M; Torralbas J; Giménez-Palop O; Caixàs A; Palao DJ; Labad J
Int Clin Psychopharmacol; 2018 Mar; 33(2):98-102. PubMed ID: 29035904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
